Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.
about
Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitisAdalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target.Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy.The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions.Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease.
P2860
Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Comparative Effectiveness of I ...... isease and Ulcerative Colitis.
@ast
Comparative Effectiveness of I ...... isease and Ulcerative Colitis.
@en
type
label
Comparative Effectiveness of I ...... isease and Ulcerative Colitis.
@ast
Comparative Effectiveness of I ...... isease and Ulcerative Colitis.
@en
prefLabel
Comparative Effectiveness of I ...... isease and Ulcerative Colitis.
@ast
Comparative Effectiveness of I ...... isease and Ulcerative Colitis.
@en
P2093
P2860
P1476
Comparative Effectiveness of I ...... isease and Ulcerative Colitis.
@en
P2093
Andrew Cagan
Ashwin N Ananthakrishnan
Elizabeth W Karlson
Guergana Savova
Katherine P Liao
Shawn N Murphy
Stanley Y Shaw
Susanne Churchill
Tianxi Cai
Vivian S Gainer
P2860
P304
P356
10.1097/MIB.0000000000000754
P50
P577
2016-03-01T00:00:00Z